Print

Purpose

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Condition

Eligibility

Eligible Ages
Between 12 Years and 63 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult individuals must be < 64 years old at Baseline Visit. Where permitted outside United States (US)/European Union (EU), adolescent individuals who are at least 12 years old at Screening may participate in Study 1 and Study 2. Adolescent individuals in the US who are at least 12 years old at Screening may participate in Study 4. - Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score >= 50 scalp hair loss at Screening and Baseline. - Severe AA with no spontaneous scalp hair regrowth over the past 6 months. - Current episode of AA of less than 8 years.

Exclusion Criteria

  • Current diagnosis of primarily diffuse type of AA. - Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium. - Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Study 1: Group 1 Upadacitinib Dose A 		Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 1: Group 2 Upadacitinib Dose B 		Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 1: Group 3 Placebo 		Participants will receive matching placebo once daily for 24 weeks in Period A.
  • Drug: Placebo
    Oral Tablets
Experimental
Study 1: Group 4 Upadacitinib Dose A 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
  • Drug: Placebo
    Oral Tablets
Experimental
Study 1: Group 5 Upadacitinib Dose B 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
  • Drug: Placebo
    Oral Tablets
Experimental
Study 1: Group 6 Placebo 		Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.
  • Drug: Placebo
    Oral Tablets
Experimental
Study 2: Group 1 Upadacitinib Dose A 		Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 2: Group 2 Upadacitinib Dose B 		Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 2: Group 3 Placebo 		Participants will receive matching placebo once daily for 24 weeks in Period A.
  • Drug: Placebo
    Oral Tablets
Experimental
Study 2: Group 4 Upadacitinib Dose A 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
  • Drug: Placebo
    Oral Tablets
Experimental
Study 2: Group 5 Upadacitinib Dose B 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
  • Drug: Placebo
    Oral Tablets
Experimental
Study 2: Group 6 Placebo 		Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.
  • Drug: Placebo
    Oral Tablets
Experimental
Study 3: Group 1 Upadacitinib Dose B (SALT > 20) 		Participants receiving upadacitinib Dose A with a SALT score > 20 at Week 52 (end of Period B) of Study 1 or Study 2 will dose escalate to upadacitinib Dose B once daily for 108 weeks.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20) 		Participants receiving upadacitinib Dose A with a SALT score ≤ 20 at Week 52 (end of Period B) of Study 1 or Study 2 will remain on upadacitinib Dose A once daily for 108 weeks.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 3: Group 3 Upadacitinib Dose B (Non-Sustained) 		Participants who end Period B on upadacitinib Dose B with a with a SALT score > 20 at Week 40 or Week 52 of Study 1 or Study 2 will remain on upadacitinib Dose B once daily for 108 weeks.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 3: Group 4 Upadacitinib Dose B (Sustained) 		Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose B once daily for 108 weeks.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 3: Group 5 Upadacitinib Dose A (Sustained) 		Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose A once daily for 108 weeks.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 4: Group 1 Upadacitinib Dose A 		US only adolescent participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 4: Group 2 Upadacitinib Dose B 		US only adolescent participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 4: Group 3 Placebo 		US only adolescent participants will receive matching placebo once daily for 24 weeks in Period A.
  • Drug: Placebo
    Oral Tablets
Experimental
Study 4: Group 4 Upadacitinib Dose A 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 4: Group 5 Upadacitinib Dose B 		Participants initially randomized to placebo (Period A) with a SALT score > 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B.
  • Drug: Upadacitinib
    Oral Tablets
    Other names:
    • Rinvoq
    • ABT-494
Experimental
Study 4: Group 6 Placebo 		Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160.
  • Drug: Placebo
    Oral Tablets

Recruiting Locations

First OC Dermatology /ID# 259220
Fountain Valley, California 92708

Dermatology Research Associates /ID# 258033
Los Angeles, California 90045

Integrative Skin Science and Research /ID# 258114
Sacramento, California 95815

University of California Davis Health /ID# 258112
Sacramento, California 95817
Contact:
Site Coordinator
916-551-2635

Clinical Trials Research Institute /ID# 258021
Thousand Oaks, California 91320-2130

Skin Care Research Boca Raton /ID# 258012
Boca Raton, Florida 33486-2269
Contact:
Site Coordinator
+1-561-948-3116

Skin Care Research - Hollywood /ID# 259210
Hollywood, Florida 33021-6748
Contact:
Site Coordinator
+1-561-948-3116

GSI Clinical Research, LLC /ID# 259352
Margate, Florida 33063

Lenus Research and Medical Group /ID# 259356
Miami, Florida 33172

Advanced Clinical Research Institute - Tampa /ID# 259204
Tampa, Florida 33607
Contact:
Site Coordinator
1-813-362-1037

Indiana University Health University Hospital /ID# 259827
Indianapolis, Indiana 46202

Tulane University School of Medicine /ID# 259799
New Orleans, Louisiana 70112
Contact:
Site Coordinator
504-988-5135

Clarkston Dermatology /ID# 258018
Clarkston, Michigan 48346

Skin Specialists /ID# 259237
Omaha, Nebraska 68144
Contact:
Site Coordinator
402-697-6599

Las Vegas Dermatology /ID# 279317
Las Vegas, Nevada 89144
Contact:
Site Coordinator
702 456 3120

Skin Cancer and Dermatology Institute - Reno /ID# 259208
Reno, Nevada 89509
Contact:
Site Coordinator
775-336-3665

Equity Medical /ID# 266680
New York, New York 10023-7340

Sadick Research Group LLC /ID# 266790
New York, New York 10075

Cleveland Clinic - Cleveland /ID# 258113
Cleveland, Ohio 44195

Dermatologists of Southwest Ohio, Inc /ID# 260116
Mason, Ohio 45040-4520
Contact:
Site Coordinator
513-701-5526

Oregon Dermatology and Research Center /ID# 258243
Portland, Oregon 97210

Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 278359
Spartanburg, South Carolina 29307
Contact:
Site Coordinator
864 574-0017 ext 8

International Clinical Research - Tennessee LLC /ID# 259552
Murfreesboro, Tennessee 37130-2450

Arlington Research Center, Inc /ID# 258028
Arlington, Texas 76011

Bellaire Dermatology Associates /ID# 259360
Bellaire, Texas 77401

U.S. Dermatology Partners - Cedar Park /ID# 259367
Cedar Park, Texas 78613
Contact:
Site Coordinator
512-260-5860

Dermatology Treatment and Research Center /ID# 259357
Dallas, Texas 75230

Dermatology Specialists of Spokane /ID# 278362
Spokane, Washington 99202

West Virginia University Hospitals /ID# 278707
Morgantown, West Virginia 26506

More Details

Status
Recruiting
Sponsor
AbbVie

Study Contact

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.